MDMB-FUBICA
Legal status | |
---|---|
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C23H25FN2O3 |
Molar mass | 396.462 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
MDMB-FUBICA is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.
It was first detected by the EMCDDA in Sweden in February 2015.[1] It is often sold in e-liquid form for use in an electronic cigarette.[2]
Side effects
MDMB-FUBICA's indazole analogue MDMB-FUBINACA has been linked to at least 1000 hospitalisations and 40 deaths as a consequence of intoxication as of March 2015.[3]
Legality
MDMB-FUBICA is banned in Sweden.[4]
See also
References
- ↑ "Hamarosan: 2015. Évi Európai Kábítószer - Jelentés" (PDF). Hungarian National Focal Point (NFP). June 2015. Retrieved 23 July 2015.
- ↑ Peace MR, Krakowiak RI, Wolf CE, Poklis A, Poklis JL (February 2017). "Identification of MDMB-FUBINACA in commercially available e-liquid formulations sold for use in electronic cigarettes". Forensic Science International. 271: 92–97. doi:10.1016/j.forsciint.2016.12.031. PMC 5511053. PMID 28076838.
- ↑ "Очередная жертва спайса". Federal Drug Control Service of the Russian Federation. 17 March 2015. Archived from the original on 14 July 2015. Retrieved 24 July 2015.
- ↑ "23 nya ämnen kan klassas som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. 1 June 2015. Retrieved 24 July 2015.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.